Showing results (1-10 of 81) with videos related to
Sort By:
Pageof 9
Clinical Pharmacokinetics|June 27, 2002
Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?Marja-Liisa DahlPharmaceuticals (Basel, Switzerland)|October 8, 2016
Implications of Inter-Individual Differences in Clopidogrel Metabolism, with Focus on PharmacogeneticsMarja-Liisa Dahl, Arzu GunesDrugs|March 18, 2004
Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implicationsKristina Melkersson, Marja-Liisa DahlPharmacogenomics|May 10, 2008
Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphismsArzu Gunes, Marja-Liisa DahlPharmacogenomics|August 13, 2013
Pharmacogenetics of olanzapine metabolismMao Mao Söderberg, Marja-Liisa DahlHuman Psychopharmacology|June 4, 2010
Impact of serotonin receptor 2A gene haplotypes on C-peptide levels in clozapine- and olanzapine-treated patientsKristina I Melkersson, Arzu Gunes, Marja-Liisa DahlCurrent Drug Metabolism|December 15, 2015
Influence of CYP3A5 polymorphism on the pharmacokinetics of psychiatric drugsGeorgia Ragia, Marja-Liisa Dahl, Vangelis G ManolopoulosEuropean Journal of Clinical Pharmacology|November 5, 2014
Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: a population-based case-control study including 1st and 2nd degree relativesKarin Hedenmalm, Arzu Gunes Granberg, Marja-Liisa DahlPharmacogenetics and Genomics|March 6, 2014
No influence of CYP3A43 rs472660G> A on steady-state serum olanzapine concentrations in white psychiatric patientsMao M Söderberg, Espen Molden, Marja-Liisa DahlJournal of Pharmaceutical and Biomedical Analysis|May 11, 2010
Liquid chromatography/tandem mass spectrometry method for determination of olanzapine and N-desmethylolanzapine in human serum and cerebrospinal fluidMartin Josefsson, Markus Roman, Elisabeth Skogh, et al.Pageof 9